Keywords: gilead, tenefovir, shows, long-term, promise, treatment-resistant, hiv
Gilead's tenefovir shows long-term promise in treatment-resistant HIV
Article | 18 April 2000
Gilead Sciences has revealed promising long-term data from a Phase IItrial of its once-daily reverse transcriptase inhibitor, tenefovir disoproxil fumarate, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
